Accendra Health, Inc.

NYSE:ACH

Medical - Distribution

Healthcare
$0.71 +3.64%

+$0.12 today

Market cap
$54.22M
Beta
1.63
P/E (TTM)
-0.2
EPS (TTM)
-$14.11
52W Low $1.84High $9.55

Volume 1.41M

Average 0.83M

ACH EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Accendra Health, Inc.NYSE: ACH

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA dips below year-ago levels

Q1 FY2026 EBITDA of $55.61M fell 7.4% year over year, behind the +949.6% change in trailing-twelve-month EBITDA. Sequentially, it fell 35.8% from the prior quarter. Over 3 fiscal years it compounded at -0.3% a year.

Context

  • EBITDA amounted to 13.2% of revenue in FY2025, up 12.7 pp from a year earlier.
  • EBITDA increased in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 4 analysts of $322.86M (-11.5%) for the fiscal year ending Dec 2026, a slowdown from the +612.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$55.61M-35.8% QoQ
Last fiscal yearDec 2025
$364.68M+612.0% YoY
LTMMar 2026
$344.06M+949.6% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-7.4%-13.7%-6.3 pp
1 year+612.0%-11.5%-623.4 pp
3-year CAGR-0.3%-5.5%-5.1 pp
5-year CAGR-3.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
364.68M USD
Year-over-year change
+612.0%
4-year CAGR
-3.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How ACH compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +949.6% is the highest of 11, against a peer median of +11.0%.
  • EBITDA amounts to 12.7% of revenue for ACH, versus a peer median of 71.8%.
ACH Competitors
EBITDA for ACH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ACHAccendra Health, Inc.LTM Mar 2026$344.06M USD+949.6%-0.3%12.7%
HITIHigh Tide Inc.LTM Apr 2026-CA$6.09M CAD-121.9%—0.9%
SGHTSight Sciences, Inc.LTM Mar 2026-$31.68M USD+27.7%—39.8%
CVRXCVRx, Inc.LTM Mar 2026-$45.97M USD-0.0%—77.8%
OMOutset Medical, Inc.LTM Mar 2026-$62.35M USD+22.0%—53.0%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-$70.61M USD-31.5%—843.9%
BIOABioAge Labs, Inc.LTM Mar 2026-$89.21M USD-28.4%—864.8%
EDITEditas Medicine, Inc.LTM Mar 2026-$100.08M USD+56.8%—258.7%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026-$160.41M USD+32.7%——
CABACabaletta Bio, Inc.LTM Mar 2026-$171.58M USD-48.1%——
CGCCanopy Growth CorporationLTM Mar 2026-CA$205.34M CAD+57.2%—65.7%
Peer median (excluding ACH) —+11.0%—71.8%

Competitors are the stored peer set for ACH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue9.79B9.96B10.33B10.7B2.76B
Cost of Revenue8.27B8.13B8.21B8.48B1.56B
Gross Profit1.51B1.83B2.13B2.22B1.2B
Gross Margin15.5%18.3%20.6%20.7%43.5%
Research & Development12.1M0000
Selling, General & Admin1.08B1.55B1.81B1.91B1.05B
Operating Expenses1.14B1.68B2.02B2.43B1.05B
Depreciation & Amortization90.62M228.67M287.38M264.78M214.52M
EBITDA415.47M368.45M390.57M51.22M364.68M
EBITDA Margin4.2%3.7%3.8%0.5%13.2%
Operating Income368.47M142.91M104.51M(207.77M)150.16M
Operating Margin3.8%1.4%1.0%-1.9%5.4%
Interest Income00000
Interest Expense48.09M128.89M157.92M143.8M129.2M
Other Income / Expenses(91.72M)(132.02M)(159.23M)(149.59M)(252.11M)
Income Before Tax276.75M10.89M(54.73M)(357.36M)(101.95M)
Pre-Tax Margin2.8%0.1%-0.5%-3.3%-3.7%
Income Tax Expense55.17M(11.5M)(13.43M)5.33M729K
Net Income221.59M22.39M(41.3M)(362.69M)(1.1B)
Net Margin2.3%0.2%-0.4%-3.4%-39.8%
EPS (Basic)3.050.30(0.54)(4.73)(14.31)
EPS (Diluted)2.940.29(0.54)(4.73)(14.31)
Weighted Avg Shares72.74M74.5M75.79M76.74M76.9M
Weighted Avg Shares (Diluted)75.49M76.22M75.79M76.74M76.9M

Accendra Health, Inc.

NYSE:ACH

Intrinsic Alpha fair value

Locked

Current Price

$0.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.